Directed migration or chemotaxis of arterial smooth muscle cells (SMC) contributes to intimal SMC accumulation, a key event in the development of atherosclerotic lesions and in restenosis after angioplasty. The present study compares and contrasts insulin-like growth factor I (IGF-I) and platelet-derived growth factor (PDGF-BB) as chemoattractants and mitogens for human arterial SMC. Compared with PDGF-BB, IGF-I is a weaker SMC mitogen. Thus, PDGF-BB, but not IGF-I, evokes a strong and rapid activation of mitogen-activated protein (MAP) kinase kinase and MAP kinase. However, IGF-I is a potent stimulator of directed migration of human arterial SMC, as measured in a Boyden chamber assay. The half-maximal concentration for migration is similar to the Kd for IGF-I receptor interaction. An IGF-I receptor-blocking antibody blocks the effects of IGF-I, IGF-II, and insulin, indicating that the effects are indeed mediated through the IGF-I receptor. The maximal effect of IGF-I on directed migration ranges between 50% and 100% of the effect of PDGF-BB, the strongest known chemoattractant for SMC. The ability of IGF-I and PDGF-BB to induce chemotaxis coincides with their ability to stimulate phosphatidylinositol turnover, diacylglycerol formation, and intracellular Ca2" flux and suggests that these signaling pathways,
Introduction
Smooth muscle accumulation is a key event in the formation and progression of lesions of atherosclerosis and in restenosis after angioplasty and bypass surgery ( 1, 2). The accumulation of arterial smooth muscle cells (SMC)' during lesion forma- 1 . Abbreviations used in this paper: ERK, extracellular signal-regulated kinase; MAP, mitogen-activated protein (kinase); MBP, myelin basic protein; PDS, plasma-derived serum; PIP2, phosphatidylinositol bisphosphate; PKI, protein kinase inhibitor; PLC, phospholipase C; SMC, smooth muscle cell(s).
tion is due to a combination of proliferation and directed migration of arterial SMC from the media into the intima (3, 4) . Both ofthese activities can be stimulated by a number ofregulatory polypeptides, produced within the lesion or derived from circulating cells. PDGF has been shown to be involved in the accumulation of SMC after balloon catheterization of the normal rat carotid artery in vivo (3) , and is present in developing lesions of atherosclerosis (5) . In vitro, PDGF-BB is a strong mitogen for arterial SMC (6) , and PDGF is a potent inducer of directed migration of SMC (7) (8) (9) .
Less interest has been focused on IGF-I in relation to a possible role in atherogenesis. The actions of IGF-I are generally mediated through the IGF-I receptor, although IGF-I in- teracts with the insulin receptor and the IGF-II receptor with lower affinity. In vitro studies show that IGF-I can be released by most cell types that contribute to atheroma formation, including arterial SMC, macrophages, and platelets (10) (11) (12) (13) . Ar- terial SMC express abundant IGF-I receptors, whereas expression ofinsulin receptors is low or absent ( 14) . IGF-I expression is increased in the artery wall after balloon angioplasty (15) (16) (17) , and thus may play a potentially important role in the response of the vascular wall to injury.
The intracellular signaling pathways involved in cell movement and directed migration are obscure, and it is unclear whether they are similar or different from those required for cell proliferation. Reorganization of the cytoskeleton and adhesion ofthe cell to extracellular matrix components are probably of importance in the migratory response of a cell to a chemoattractant. Recent reports indicate links between the phosphatidylinositol pathway, actin fiber formation and cell migration (for review see references 18 and 19) . Phosphatidylinositol turnover is stimulated by various chemoattractants (20, 21 ) . Furthermore, stimulation ofthe phosphatidylinositol pathway does not seem to be absolutely required for proliferation induced by PDGF-BB (22) . In contrast, activation of a signaling pathway involving the mitogen-activated protein (MAP) kinase, and the activator MAP kinase kinase, has been suggested to be of importance in PDGF-induced proliferation (23) .
The aim of the present study was to determine whether IGF-I mediates chemotaxis of human arterial SMC, and to compare the relative effects of IGF-I with PDGF-BB, both of which have been implicated in atherogenesis. The possibility of distinct intracellular signaling pathways involved in chemotaxis versus proliferation also prompted investigation of some of the signaling events that follow activation of IGF-I and PDGF receptors.
Methods
Cell cultures. Human newborn (2 d to 3 m) arterial SMC were obtained from the thoracic aortas of infants after accidental death, the sudden infant death syndrome, or congenital defects. Arterial SMC from adult thoracic aortas were obtained from normal donor heart transplants. The cells were isolated by the explant method and cultured as described previously (24) . Cells were used in passages 2-10, and were characterized as smooth muscle by morphologic criteria and by expression of smooth muscle a-actin. The cells were negative in mycoplasma assays, and had a normal chromosome number. Three different strains ( Migration assay. The migration and chemotaxis ofcells were quantified using a 48-well micro-Boyden chamber apparatus (Neuroprobe Inc., Cabin John, MD). Growth factors were diluted in DME with 0.25% BSA and loaded into the lower wells of the Boyden chamber in triplicates. The wells were subsequently covered with a polyvinylpyrrolidone (PVP)-free filter with 8-,um pores (Nucleopore Corp., Pleasanton, CA) coated with type I collagen (Vitrogen, Collagen Corp., Palo Alto, CA). Confluent cell cultures were washed four times in PBS and trypsinized (trypsin diluted 1:5 to a final concentration of 0.01% trypsin/0. 11 mM EDTA) for the minimum period of time required to obtain a monocellular suspension. The cells were washed twice in DME/0.25% BSA, and resuspended at a density of 1 To compare the effects of trypsinization on PDGF and IGF-I binding site number and affinities, cells were treated exactly as for the migration assay, i.e., they were trypsinized (1:5 dilution of trypsin), plated in Vitrogen-coated 24-well trays, and were allowed to adhere for 30 min at 370C. In parallel, nontrypsinized cells in 24-well trays were assayed. Other experiments were set up to study whether IGF-I affects binding of PDGF-BB or PDGF-AA. Cells were preincubated with 1 nM IGF-I for 2 or 4 h at 370C, and binding studies performed as described above.
Inositol monophosphate accumulation and measurement ofphosphatidylinositol and diacylglycerol lipid masses. For measurement of inositol monophosphate formation, cells in 6-well plates were incubated in DME/ 1% human PDS for 24 100 ,tl TCA (100%) was added, the solubilized medium was extracted four times with ether, and neutralized extracts applied to BioRad Laboratories (Richmond, CA) 1-X8 AG columns (formate form, 100-200 mesh). After elution of unincorporated inositol and glycerophospho-derivates, inositol monophosphate was eluted in 0.2 M ammonium formate and 0.1 M formic acid, and radioactivity was subsequently measured.
For measurements of phosphatidylinositol biphosphate (PIP2) and diacylglycerol lipid mass, cells in 100 mm-dishes were incubated in DME/ 1% human PDS for 2 d, and for an additional 12 h in DME without PDS or BSA. The cells were then stimulated with 10 nM IGF-I or 1 nM PDGF-BB. At the indicated times, the medium was removed and the lipids were extracted with ice-cold methanol. High-performance liquid chromatography analysis was performed with a 0.45 x 25 cm g-Porasil silica column (Waters Associates, Milford, MA) (26) .
The mobile phase consisted of a gradient of 1-9% water in hexane/ isopropanol (3:4, vol/vol) run at a flow rate of 1 ml/min. This was found to give adequate separation of diacylglycerol, phosphatidic acid, phosphatidylethanolamine, phosphatidylinositol, phosphatidylserine, phosphatidylcholine, and sphingomyelin. Lipids in column effluent were monitored at 260 nm. The fractions were also analyzed for phosphorus content, amines, and acyl esters according to established methods (27, 28) .
Measurement ofintracellular calcium levels. Intracellular Ca2+ levels were measured according to Grynkiewicz et al. (29) . In short, SMC were trypsinized and suspended in Hanks' medium/0.1% BSA buffered with Hepes (pH 7.4), and subsequently incubated with 2,uM Fura 2-acetoxymethylester for 1 h at room temperature. Fluorescence was measured as a 340/ 380 nm ratio after PDGF-BB or IGF-I stimulation of the cells in the presence or absence of 2 mM EGTA at 37°C in a CAF-100 Ca2' analyzer (JASCO, Tokyo, Japan).
Measurement of MAP-kinase and MAP-kinase kinase activity. Cells in 100-mm dishes (-5 million cells) were incubated in DME/ 1% human PDS for 2 d. The cells were washed twice in DME/0.25% BSA, and stimulated with growth factors for the indicated periods of time. Immediately after stimulation, the cells were washed twice in ice-cold PBS, once with buffer H containing 50 mM fl-glycerophosphate, pH 7.4, 1.5 mM EGTA, 0.1 mM Na3VO4, 1 mM DTT, 10 ,ug/ml aprotinin, 5 Ag/ml pepstatin, 20 ,g/ml leupeptin, and 1 mM benzamidine, scraped off the plates, and sonicated in 0.5 ml buffer H for 20 s. After sonication the cell extracts ( -0.7 ml) were centrifuged at 100,000 g for 20 min at 4VC in a model TL-100 ultracentrifuge (Beckman Instruments, Inc., Fullerton, CA) and the supernatants ( 1 mg protein/ml) were saved for kinase assays.
Cell extracts (5 Ml) were assayed for MAP kinase activity in a solu- (Fig. 3) . It did not, however, block the migratory or chemokinetic response to PDGF-BB (Table I) . Comparison of chemotactic and growth-promoting effects induced by IGF-I and PDGF-BB. When tested in the same experiments, IGF-I is typically able to induce -50% of the maximal migratory effect observed with PDGF-BB. Similar migratory responses to IGF-I and PDGF-BB were observed with arterial SMC obtained from newborn thoracic aorta (Fig.  2 A) , as compared with adult thoracic aorta (Fig. 2 B) . In one strain (newborn) the effect of IGF-I was comparable to the maximal effect observed with PDGF-BB (the maximal-fold increase in migration induced by IGF-I was 1.62±0.09 and by PDGF-BB was 1.72±0.08, n = 4).
To determine whether IGF-I increases migration by modulation of PDGF receptor numbers or affinities, binding studies (Fig. 4) . Furthermore, whereas the maximal concentration of PDGF-BB is approximately the same for migration and DNA synthesis (ED50 = 0.05 and 0.08 nM, respectively), concentrations of IGF-I required to stimulate DNA synthesis are 5-10 times higher, as compared with stimulation of migration (ED.IJ = 1 nM and 0.08-0.2 nM, respectively). Insulin is 60 times less potent than IGF-I in stimulating DNA synthesis, with a maximal response at 1 uM (Fig. 4) . IGF-II stimulates DNA synthesis to a maximal level similar to that of IGF-I, but the ECe value is approximately three times higher (data not shown). Similar results on DNA synthesis are obtained when the growth factors are added in the absence of 1% human PDS to minimize the possible contribution of plasma IGF-I and IGF-binding proteins. The stimulation of DNA synthesis by PDGF-BB is reflected by an -40% increase in cell number 3 d after addition ofPDGF-BB ( 1 nM), whereas cell number is not significantly increased 3 d after stimulation with 10 nM IGF-I (data not shown).
IGF-I, PDGF-BB, and PDGF-AA binding sites and affinities. The SMC cells used (newborn) express 15,000 high-affinity (Kd 0.1 nM) binding sites for IGF-I (Fig. 5 A) . This is in the same order of magnitude as the number of PDGF receptor a-subunits (Fig. 5 B) , but -15 times lower than the expression level of high affinity (Kd = 0.1 nM) binding sites for PDGF-BB (Fig. 5 C) . High-affinity binding of [1251 ](A 14) monoiodinated human insulin (Amersham International) could not be detected in several independent experiments. To investigate the effect of the trypsinization procedure used for the migration assay on the different receptors, cells were treated exactly as for migration studies, and the number and affinities of binding sites were compared with nontrypsinized cells. Trypsinization does not affect binding of IGF-I (Fig. 5 A) , whereas the binding of both PDGF-AA and PDGF-BB was about half of that observed in nontrypsinized cells (Fig. 5, B and C). This is likely to be due to a decreased number of binding sites, since the affinities ofthe high affinity binding sites are not significantly affected by trypsinization as estimated with Scatchard plots (inserts, Fig. 5 , B and C). IGF-I in human arterial°2
. Ability ofIGF-I and PDGF-BB to induce chemotaxis correlates with their ability to stimulate phosphatidylinositol turnover, diacylglycerol formation, and intracellular calcium release. Both PDGF-BB and IGF-I stimulate inositol monophosphate formation in newborn aortic SMC. The concentrations of IGF-I and PDGF-BB required to stimulate inositol monophosphate formation are similar to the concentrations that stimulate chemotaxis (Table II and Fig. 2) . The increased inositol monophosphate formation is reflected by an early (maximal effect 15-45 s after stimulation) increase in diacylglycerol formation and a reciprocal decrease in PIP2 lipid mass after stimulation by either IGF-I or PDGF-BB (Fig. 6, A and B) . Neither PDGF-BB, nor IGF-I affect phosphatidylcholine or phosphatidylethanolamine lipid mass over the studied period of time (data not shown). Stimulation of phosphatidylinositol turnover by IGF-I and PDGF-BB is associated with an increased intracellular [Ca2+ ] as shown by Fig. 7 . Subnanomolar concentrations ofeither IGF-I or PDGF-BB stimulate Ca2+-release, with a maximal effect reached 10-40 s after stimulation (Fig. 7 A) . The EC50 values of IGF-I and PDGF-BB, as esti- mated from the dose-response curves, are 0.27 and 0.38 nM, respectively (Fig. 7 B) . The rise in intracellular [Ca2"] is likely due to release from intracellular compartments, since both IGF-I and PDGF-BB give rise to similar Ca2+ transients in the presence of 2 mM EGTA (data not shown).
PDGF-BB, but not IGF-I, is a strong activator ofthe MAP kinase cascade. The pattern of responses to PDGF-BB versus IGF-I is quite different when activation of MAP kinase kinase or MAP kinase are assessed. PDGF-BB (1 nM) evokes a marked activation of both MAP kinase and MAP kinase kinase, whereas 10 nM IGF-I does not (Figs. 8 and 9 ). Activation of MAP kinase kinase and MAP kinase is maximal 5 min after addition of PDGF-BB, and the time course of activation of MAP kinase kinase shows a more rapid decrease in activity compared with MAP kinase. Dose-response curves reveal that the EDo values for PDGF-BB activation of both MAP kinase (ED50 = 0.12 nM) and MAP kinase kinase (ED50 = 0.1 1 nM) are similar to the Kd of receptor binding (Fig. 9) . IGF-I has little effect on MAP kinase kinase and MAP kinase within a broad range of concentrations in cells adherent to plastic as shown in Fig. 9 , nor are they significantly activated when the cells are plated under conditions used for the migration studies. Similar effects are observed when a specific synthetic peptide (ST 1) RRRELVEPLTPSGEAPN (the MAP kinase phosphor- 
Discussion
The IGF-I receptor mediates SMC chemotaxis. The present study shows that IGF-I is a potent stimulant of directed migration, or chemotaxis, of both newborn and adult human aortic SMC obtained from several donors. IGF-II and insulin are able to induce the same maximal migration, although they are 6 and 400 times less potent than IGF-I, respectively. In previous studies on different cell lines, IGF-II was reported to be able to stimulate migration through both the IGF-I receptor (31 ) and the IGF-II receptor (32 ( 31, 38, 39 ) . These data, together with the results ofthe present study, show that IGF-I can act as a chemoattractant for various types of epithelial and mesenchymal cells.
Stimulation of SMC migration by IGF-I and PDGF-BB. The level of SMC migration induced by IGF-I ranges between 50% and 100% of the maximal response obtained with PDGF, the strongest chemoattractant for arterial SMC described to date. The chemotactic effect of IGF-I has recently been shown to be of a similar magnitude as that of PDGF-BB in another mesenchymal cell type; rat periodontal ligament fibroblastic cells (37) . The lower maximal effect of IGF-I we observed compared to PDGF-BB may result from the lower number of high affinity binding sites for IGF-I on these cells. Although PDGF-BB binding sites are decreased after the trypsinization procedure used for migration studies, the number is still about five times higher than for IGF-I. Further support for this interpretation comes from the observation in a single isolate ofnewborn SMC in which PDGF-BB and IGF-I induced a similar maximal migratory response, in which the number of PDGF-BB binding sites is -40% of that observed in the strain shown in Fig. 2 A. Regardless, IGF-I is a potent chemoattractant for cultured human arterial SMC.
The potential importance of migration in lesion formation has been highlighted by in vivo studies implicating PDGF in the neointima that forms in the rat carotid artery within 2 wk after balloon angioplasty. In vivo administration ofanti-PDGF antibody after balloon injury of the rat carotid decreases intimal accumulation of SMC by > 40% with no decrease in the labeling index in the neointima or the media in the time window of labeling examined (3). These studies, together with gentle injury studies in which PDGF was administered to the injured rat carotid artery (4) , suggest that the effect of PDGF on intimal thickening may result primarily from stimulation of SMC migration from the media into the intima. Migration stimulated by IGF-I may also contribute to this accumulation.
Intracellular signaling pathways involved in chemotaxis versus proliferation. The signal transduction pathways from the PDGF and IGF-I receptors, and the molecular mechanisms required to stimulate chemotaxis versus proliferation are not completely understood. Recent studies have shown that phosphoinositides bind several actin-binding proteins, and indicate that phosphatidylinositol turnover may be associated with the cytoskeletal reorganization required for chemotaxis (40, 41; for review see 18, 19) . We, therefore, asked whether phosphatidylinositol turnover may be involved in the chemotactic response of SMC. Indeed, both PDGF-BB and IGF-I were found to stimulate phosphatidylinositol turnover, diacylglycerol formation and intracellular Ca2 -release.
PDGF-BB-induced phosphatidylinositol turnover is likely to involve activation ofphospholipase Cy (PLC-y) after association of src homology 2 (SH2) domains in PLCy with specific phosphorylated tyrosine residues in the carboxy-terminal portion of the PDGF p-receptor (22) . PDGF ,-receptor mutants lacking the PLCy-binding tyrosine residues are able to induce the same maximal mitogenic response as the wild-type receptor, suggesting that activation of PLCy is not an absolute prerequisite for PDGF induced proliferation (22) , although redundant signaling pathways from the PDGF receptor f3-subunit that lead to mitogenesis most likely exist (42) .
The mechanism of IGF-I-induced phosphoinositol turnover is less clear, but may, under some circumstances, involve activation of PLC, rather than PLCy (43) . In many cell lines, IGF-I does not induce inositol trisphosphate formation, and one of the IGF-I receptor signaling mediators (insulin receptor substrate 1 ) does not appear to bind SH2-fusion proteins containing PLC7-SH2 domains in vitro (44) . However, in some primary cell types, such as cardiac myocytes and thyroid cells, IGF-I stimulates inositol trisphosphate formation (45, 46) . The mechanism of IGF-I-induced phosphatidylinositol turnover in SMC remains to be elucidated. The mitogenic effects of various growth factors, acting through tyrosine kinase receptors, may be dependent on activation of a pathway involving p21 Ras and the MAP kinase cascade (47, reviewed in reference 48 and references therein). The present study shows that in human arterial SMC, PDGF-BB is a potent mitogen and a strong activator of the MAP kinase cascade, whereas IGF-I is not. Taken together, these results suggest that activation of MAP kinase, after PDGF receptor activation, is involved in PDGF-BB mitogenic signaling whereas our results further imply that activation of the MAP kinase pathway is not required for chemotaxis of human SMC.
In contrast to the present study, IGF-I has been reported to activate MAP kinase signaling in other cell types (49) , and insulin is known to activate the MAP kinase cascade (50, 51 ) . The lack of effect of IGF-I in the SMC may very well be cell type specific, and does not reflect a low IGF-I receptor number, since PDGF-AA gives a marked activation of the MAP kinase cascade, despite similar receptor numbers. The effects of IGF-I on SMC DNA synthesis may, at least in part, be due to activation of intracellular pathways distinct from the MAP kinase pathway. This is in line with the observation that mitogenic effects of PDGF and IGF-I are additive in SMC (52).
The present study shows a correlation ofthe ability ofIGF-I and PDGF-BB to induce phosphatidylinositol turnover, diacylglycerol formation, and Ca2"-release from intracellular compartments during chemotaxis of human arterial SMC. In contrast, IGF-I does not share the potency of PDGF-BB to activate the MAP kinase cascade and induce SMC proliferation. Further studies will be required to establish the extent of the differences in signaling pathways involved in chemotaxis versus proliferation.
